Your browser doesn't support javascript.
loading
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
Heymach, J V; Lockwood, S J; Herbst, R S; Johnson, B E; Ryan, A J.
Afiliação
  • Heymach JV; Division of Cancer Medicine, Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA.
  • Lockwood SJ; Oncology iMED, AstraZeneca, Macclesfield, UK.
  • Herbst RS; Section of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, Yale, New Haven.
  • Johnson BE; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA; Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA.
  • Ryan AJ; Department of Oncology, University of Oxford, Oxford, UK. Electronic address: anderson.ryan@oncology.ox.ac.uk.
Ann Oncol ; 25(10): 1941-1948, 2014 Oct.
Article em En | MEDLINE | ID: mdl-25057173
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article